Sanofi

Sanofi(SNY)

PARIS, France
Pharmaceutical1 H-1B visas (FY2023)

Focus: Small Molecules, Biologics

Sanofi is a life sciences company focused on Small Molecules, Biologics.

ImmunologyOncologyNeurologyRare DiseasesVaccines
Funding Stage
PUBLIC
Employees
91,000
Open Jobs
1126

Products & Portfolio (16)

34 discontinued products not shown

ADLYXIN
lixisenatide
Peak
PeptideSUBCUTANEOUS · SOLUTION
100/33 SOLIQUA 100/33 is a combination of insulin glargine, a basal insulin analog, and lixisenatide, a GLP-1 receptor agonist. Insulin glargine The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis. Lixisenatide Lixisenatide is a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
type 2 diabetes mellitus
2016
30
ADMELOG
insulin lispro
Peak
INTRAVENOUS, SUBCUTANEOUS · SOLUTION
analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
glycemic control in adult
2017
30
ADMELOG SOLOSTAR
insulin lispro
Peak
SUBCUTANEOUS · SOLUTION
analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
glycemic control in adult
2017
30
ALLEGRA ALLERGY
fexofenadine hydrochloride
LOE Approaching
ORAL · TABLET
hivesrelieves itching due to hives (urticaria)an allergic skin reaction from occurring
2000
30
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride and pseudoephedrine hydrochloride
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
these symptoms due to hay feverother upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchywatery eyes ▪ itching of the nose+4 more
1997
30
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride and pseudoephedrine hydrochloride
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
these symptoms due to hay feverother upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchywatery eyes ▪ itching of the nose+4 more
2004
30
APIDRA
insulin glulisine
LOE Approaching
INTRAVENOUS, SUBCUTANEOUS · INJECTABLE
analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
glycemic control in adult
2004
30
APIDRA SOLOSTAR
insulin glulisine
LOE Approaching
SUBCUTANEOUS · INJECTABLE
analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
glycemic control in adult
2004
30
ARAVA
leflunomide
LOE Approaching
ORAL · TABLET
(a mitochondrial enzyme involved in de novo pyrimidine synthesis) and has antiproliferative activity. Several in vivo and in vitro experimental models have demonstrated an anti-inflammatory effect.
rheumatoid arthritis
1998
30
AUBAGIO
teriflunomide
Peak
ORAL · TABLET
Dihydroorotate Dehydrogenase Inhibitors
relapsing forms of multiple sclerosis (MS)to include clinically isolated syndromerelapsing-remitting disease+2 more
2012
0
AVAPRO
irbesartan
LOE Approaching
ORAL · TABLET
Angiotensin 2 Receptor Antagonists
hypertensionto lower blood pressurediabetic nephropathy in patients with type 2 diabetes+3 more
1997
30
CAMPATH
alemtuzumab
LOE Approaching
mAbINTRAVENOUS · VIAL
CD52-directed Antibody Interactions
leukemia
2001
30
View all 16 products

Pipeline & Clinical Trials

Efluelda® Pre-filled syringe
Influenza Immunization
N/A
Clinical Trials (1)
NCT07282795Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
N/A
Investigational Procedures
Sphingomyelin Lipidosis
N/A
Clinical Trials (1)
NCT04106544A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)
N/A
swab sampling
Influenza, Human
N/A
Clinical Trials (1)
NCT04244500Burden of Influenza at Emergency Department (ED) Level in European Countries
N/A
N/A
Clinical Trials (5)
NCT00474838Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy
Phase 4
NCT00489190APIDRA Registration Study
Phase 4
NCT00911625Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Phase 4

+2 more

Kidney Information Network for Disease Research and Education
ESRD
N/A
Clinical Trials (1)
NCT03321604Kidney Information Network for Disease Research and Education
N/A
Observatory on Elderly Patients "Les S.AGES"
Diabetes Mellitus, Type 2
N/A
Clinical Trials (1)
NCT01065909Observatory on Elderly Patients "Les S.AGES"
N/A
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registr
Acute Leukemia
N/A
Clinical Trials (2)
NCT01362985Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor
N/A
NCT01362972Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor
N/A
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Optic Neuritis
N/A
a live attenuated chimeric JE vaccine
Japanese Encephalitis
N/A
Clinical Trials (2)
NCT02526550Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
Phase 4
NCT02602652Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine
N/A
Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials
Peripheral Arterial Occlusive Disease
N/A
Clinical Trials (1)
NCT01135797Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials
N/A
Bevacizumab
Lung Cancer
N/A
Clinical Trials (5)
NCT00116506Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Phase 2
NCT00881504A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
Phase 2
NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/2

+2 more

N/A
Flublok Quadrivalent influenza vaccine RIV4
Influenza
N/A
Clinical Trials (1)
NCT04460781Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
N/A
DUPIXENT®
Asthma
N/A
Clinical Trials (2)
NCT04287621Registry of Asthma Patients Initiating DUPIXENT®
N/A
NCT06099704Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
N/A
RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
Hypertension
N/A
Clinical Trials (1)
NCT00258921RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
N/A
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Meningitis
N/A
Clinical Trials (1)
NCT01689155Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children
N/A
Clinical Trials (1)
NCT01738373Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
N/A
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Prostatic Neoplasms
N/A
Clinical Trials (1)
NCT01076751Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
N/A
Clinical Trials (1)
NCT06892704Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
N/A
A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatmen
Asthma
N/A
Clinical Trials (1)
NCT05070663A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
N/A
N/A
Clinical Trials (1)
NCT03388034Pertussis Immunization Programs in Low Income Countries - Ivory Coast
N/A
N/A
Clinical Trials (3)
NCT00813397Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.
N/A
NCT00778479Evaluation of the Safety of Sepraspray in Open Abdominal Surgery
N/A
NCT00624390Sepraspray™ Laparoscopic Myomectomy Study
N/A
Brigham and Women's Rheumatoid Arthritis Sequential Study
Rheumatoid Arthritis
N/A
Alglucosidase alfa GZ419829
Glycogen Storage Disease Type II
N/A
Clinical Trials (1)
NCT04848779A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
N/A
Clinical Trials (5)
NCT02004691Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Phase 2/3
NCT02004704A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Phase 2
NCT06949358A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France
Phase 2

+2 more

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 m
Primary Hypercholesterolaemia and Mixed Dyslipidaemia
N/A
Clinical Trials (1)
NCT05129241Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
N/A
A Screening Study Evaluating Disease Status of Gaucher Type I Patients
Gaucher Disease, Type 1
N/A
Clinical Trials (1)
NCT00795197A Screening Study Evaluating Disease Status of Gaucher Type I Patients
N/A
Clinical Trials (1)
NCT00344825Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)
N/A
Blood sampling
Septic Shock
N/A
Clinical Trials (2)
NCT02638779REAnimation Low Immune Status Markers
N/A
NCT00929318Influence of Thyroid Hormones on the Woundhealing Process
N/A
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease
Fabry Disease
N/A
Clinical Trials (1)
NCT06325488Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease
N/A
intradermal pholcodine allergy test in cases
Neuromuscular Blocking Agents Anaphylaxis
N/A
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients
Medication Non-adherence
N/A
Clinical Trials (1)
NCT00998127Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients
N/A
Insulin glargine
Diabetes
N/A
Clinical Trials (1)
NCT03703869Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
N/A
Gaucher disease DNA mutation analysis
Gaucher Disease
N/A
Clinical Trials (1)
NCT02785744Genzyme Osteopenia/Osteoporosis Study
N/A
Digital Gaucher Platform
Gaucher Disease
N/A
Clinical Trials (1)
NCT04997772Digital Health Platform Customized for Patients With Gaucher Disease
N/A
Understanding MRI in MS
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT03872583Understanding Magnetic Resonance Imaging in Multiple Sclerosis
N/A
Clinical Trials (1)
NCT06693531A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
N/A
insulin Glargine + Insulin Apidra
Diabetes Type 1
N/A
Clinical Trials (1)
NCT00925977Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
N/A
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
Heparin-induced Thrombocytopenia
N/A
Clinical Trials (1)
NCT00748839Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
N/A
T1 Weighted MRI
Myelofibrosis
N/A
Clinical Trials (1)
NCT01973881Quantitative MRI for Myelofibrosis
N/A
Clinical Trials (1)
NCT00394524Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU
N/A
Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
Osteoporosis
N/A
Clinical Trials (1)
NCT00816452Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
N/A
ALIROCUMAB SAR236553
Hypercholesterolemia
N/A
Clinical Trials (1)
NCT03379558Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study
N/A
N/A
Clinical Trials (1)
NCT00452985Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
N/A
Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients
Acne
N/A
Clinical Trials (1)
NCT07411638Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients
N/A
Clinical Trials (1)
NCT00291811Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization
N/A
Clinical Trials (1)
NCT06481904Registry for Stage 2 Type 1 Diabetes
N/A
docetaxel + CEF
CYP3A Phenotyping
N/A
Clinical Trials (1)
NCT01110291Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
N/A
Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patie
Pompe Disease
N/A
Clinical Trials (1)
NCT00113035Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease
N/A
Venous Thromboembolism Taskforce Audit Program
Venous Thrombosis
N/A
Clinical Trials (1)
NCT00535171Venous Thromboembolism Taskforce Audit Program
N/A

Open Jobs (1126)

Clinical Operations Study Country Lead (COSCL)

Tokyo
Clinical Operations
Yesterday

Computerized System Validation Engineer

Zeralda
Quality
2d ago

Head of Automation& Manufacturing Systems

Zeralda
Manufacturing
2d ago

糖尿病事业部-医学信息沟通代表-杭州

Hangzhou
2d ago

Computational Scientist - Bioinformatician

Cambridge, MA
Data Science & AI
3d ago
$122K - $177K/yr

Digital R&D Veeva CoE Lead

Hyderabad
Research & Development
3d ago

疫苗事业部-区域市场经理-西安

Xian
4d ago

Medical - Real-World Evidence Data Scientist - Shanghai

Shanghai
Data Science & AI
4d ago

Medical - Real-World Evidence Data Scientist - Beijing

Beijing
Data Science & AI
4d ago

Medical - Manager, Real World Investigator-Shanghai

Shanghai
4d ago

Medical - Manager, Real World Investigator - Shanghai

Shanghai
4d ago

特药事业部-医学信息沟通代表-广州

Guangzhou
4d ago

特药事业部-医学信息沟通代表-南充

Nanchong
4d ago

M&S-QC Analyst Physico Chemistry-Beijing

Beijing
Manufacturing
4d ago

Global Medical Product Lead

Morristown, NJ
4d ago
$179K - $258K/yr

Biologics Operations Summer Intern

Waterford
Manufacturing
4d ago

Director - Medical Portfolio Strategy & Solutions

Cambridge, MA
Business Development
4d ago
$206K - $298K/yr

Field Medical Director, Oncology East

Cambridge, MA
Medical Affairs
4d ago
$206K - $298K/yr

Privacy Officer and Counsel

Morristown, NJ
4d ago
$179K - $258K/yr

Platform Engineer

Toronto, ON
Engineering
4d ago

Technicien de Conditionnement et Contrôle (2x7h)

Montpellier
4d ago

Manufacturing Summer Student

Waterford
Manufacturing
4d ago

Director, Commercial Transformation

Cambridge, MA
Commercial
4d ago
$161K - $233K/yr

Data and AI Engineering Manager - Core Digital Products

Toronto, ON
Engineering
4d ago
$125K - $209K/yr

Commercial Lead EP

Buenos Aires
Commercial
4d ago
View all 1126 open positions →
Interview Prep Quick Facts
Portfolio: 194 approved products, 162 clinical trials
Top TAs: Oncology, Metabolic Diseases, Infectious Diseases
H-1B (2023): 1 approval
Publications: 25 in PubMed
Open Roles: 1126 active jobs
Portfolio Health
Pre-Launch31 (16%)
Launch2 (1%)
Growth2 (1%)
Peak20 (10%)
LOE Approaching123 (63%)
Post-LOE16 (8%)
194 total products
Therapeutic Area Focus
Oncology
8 marketed749 pipeline
Metabolic Diseases
15 marketed396 pipeline
Infectious Diseases
5 marketed359 pipeline
Rare Diseases
5 marketed152 pipeline
Neurology
4 marketed143 pipeline
Cardiovascular
7 marketed103 pipeline
Respiratory
13 marketed93 pipeline
Immunology
7 marketed70 pipeline
Marketed
Pipeline

Hiring Trend

Actively Hiring
1126
Open Roles
+1126
Added
-0
Filled/Removed

Based on last 2 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub